T 1569/22 (Neoantigens/DANA-FARBER) of 08.10.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T156922.20241008
- Date of decision
- 8 October 2024
- Case number
- T 1569/22
- Online on
- 28 November 2024
- Petition for review of
- -
- Application number
- 15198284.0
- IPC class
- A61K 39/00A61P 35/00G01N 33/68
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Compositions of tumor specific neoantigens for use in treating tumours
- Applicant name
- The General Hospital Corporation
Dana-Farber Cancer Institute, Inc. - Opponent name
- James Poole Limited
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1)
- Keywords
- Remittal - deficiency in first-instance proceedings (yes)
- Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division for further prosecution.